Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | Next steps for the CD8 ImmunoPET minibody

Ian A. Wilson • 12 Nov 2021
SITC 2021
General

Ian A. Wilson, PhD, ImaginAb Inc., Los Angeles, CA, discusses how the CD8 ImmunoPET antibody fragment, known as a ‘minibody’ will evolve and how it may be used in the future. This technology has been developed to measure physical immune response status using CD8 as a marker. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

More from Ian A. Wilson

1:09
Addressing unmet clinical needs with the CD8 ImmunoPET minibody
Ian A. Wilson • 12 Nov 2021
1:03
Latest developments in radiopharmaceutical therapies
Ian A. Wilson • 12 Nov 2021

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals